Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →
CLEATUS
Get CLEATUS

Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)

Active
RFA-AI-28-024Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking proposals under solicitation RFA-AI-28-024 to accelerate the research and preclinical development of next-generation malaria vaccines. This initiative focuses on utilizing structure-based immunogen design, advanced formulations, and combination vaccines to create long-lasting and highly effective protection. The ultimate objective is to enhance public health security in the United States and establish a developmental model that can be applied to other mosquito-borne diseases. This federal solicitation was posted on October 13, 2026, with a response deadline of February 12, 2027. The funding opportunity follows an R61/R33 structure and specifically notes that clinical trials are not allowed. Interested parties can find further details and submission guidelines through the official grants portal.

General Info

NIAID seeks proposals for next-generation malaria vaccine research and preclinical development by February 2027.

Agency

National Institutes Of Health → National Institute Of Allergy And Infectious Diseases

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyNational Institutes Of Health → National Institute Of Allergy And Infectious Diseases
ContactsNo contacts available
OfficeUSA
Organization / AgencyNational Institutes Of Health → National Institute Of Allergy And Infectious Diseases
Office AddressUSA
ContactsNo contact information available

Full Description

Show more
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Preclinical & Translational Research SupportThis subcontract for Preclinical and Translational Research Support involves providing specialized laboratory services and preclinical testing to prime contractors working on Defense Health Agency lupus research projects. The scope of work focuses on supporting the transition from laboratory research to clinical application through the development of animal models, in-vitro and in-vivo modeling, and preclinical toxicity testing. The primary deliverables include validated models and comprehensive preclinical test results. The project is managed under the Department of Defense for the Defense Health Agency and is categorized under NAICS code 541714. Performance of the contract will take place in Frederick, Maryland. Interested parties should note the response deadline of November 16, 2026.
Defense Health Agency

POSTED

about 24 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Patient Quality of Life (QoL) Clinical StudiesThis subcontract focuses on conducting patient-centric clinical research for the Defense Health Agency to evaluate factors affecting the quality of life for lupus patients. The scope of work includes comprehensive clinical trial management, the design of patient surveys, psychosocial assessments, and detailed health outcomes research. The primary objective is to generate and deliver clinical study reports and outcome data to prime contractors. The project is categorized under NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the response deadline is November 16, 2026, following a posting date of October 14, 2026.
Defense Health Agency

POSTED

about 24 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Disease Mechanism & Intervention ResearchThis subcontract opportunity involves conducting specialized research into lupus disease mechanisms and analyzing patient responses to medical interventions to support prime contractors on Defense Health Agency projects. The scope of work focuses on translational research, pharmacological studies, and the mapping of disease pathways to deliver critical analysis of intervention response data. The project is associated with NAICS code 541714 and will be performed in Frederick, Maryland. Interested parties should note that the solicitation was posted on October 14, 2026, with a response deadline set for November 16, 2026.
Defense Health Agency

POSTED

about 24 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Lupus Genetic & Biological Subset ResearchThe Lupus Genetic and Biological Subset Research subcontract involves providing specialized biological and genetic analysis to support prime contractors on Defense Health Agency research projects. The scope of work focuses on identifying and categorizing lupus patient subsets to enable targeted treatment through genomic sequencing, biomarker identification, biological assay development, and detailed patient cohort analysis. The primary deliverable for this effort is the provision of categorized biological and genetic data sets. This project is managed under the Department of Defense for the Defense Health Agency, with performance taking place in Frederick, Maryland. The opportunity was posted on October 14, 2026, with a response deadline of November 16, 2026. The work is classified under NAICS code 541714, reflecting its focus on research and development in the biotechnology field.
Defense Health Agency

POSTED

about 24 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
RFI Lupus Research Program (LRP) Public
Solicitation # HT9427RFI2027LRP
The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information under solicitation number HT9427RFI2027LRP to gather feedback for the Lupus Research Program. This initiative aims to inform future focus areas and research funding opportunities for fiscal year 2027. The program is specifically seeking input from academia, industry, non-profit organizations, federal agencies, and the general public to identify critical gaps in the field and underfunded research areas. Strategic goals include improving the quality of life for patients, gaining insight into disease mechanisms and heterogeneity, and advancing the understanding of lupus patient subsets to optimize treatment. This action is strictly for information and planning purposes and does not constitute a formal solicitation, request for proposals, or request for quotations. Consequently, no contract will be awarded based on this announcement, and there are no established deliverables or periods of performance. Interested parties are requested to provide their feedback via Survey Monkey by November 16, 2026, at 4:00 PM EST. While previous appropriations from fiscal years 2017 through 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated.
Defense Health Agency

POSTED

about 24 hours ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
DARPA Surgical Competition (DSC) Second Industry Day
Solicitation # DARPA-SN-27-02
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is hosting a Second Industry Day for the DARPA Surgical Competition (DSC) under solicitation number DARPA-SN-27-02. This virtual event is scheduled for November 4, 2026, from 4:00 PM to 6:00 PM Eastern Time, with a registration deadline of November 2, 2026. While this notice is not a formal solicitation for proposals, it serves to engage potential competitors in a competition aimed at establishing the state of the art for open, robotic trauma surgery and developing a minimum viable product for scalable, autonomous robotic surgical assistance. The competition will evaluate platforms across three primary performance lanes: Component Gates, which assess system safety and autonomy through medical knowledge, physical capability, and rapid learning; Surgical Collaboration, which tests the ability to work alongside a human surgeon; and Surgical Independence, which evaluates the platform's ability to independently plan and execute end-to-end trauma procedures. The DSC will be conducted at the unclassified level. Technical and administrative inquiries are directed to Program Manager Jeremy Pamplin at SurgicalCompetition@darpa.mil.
Defense Advanced Research Projects Agcy

POSTED

about 24 hours ago

DEADLINE

in 18 days
View Details
NAICS: 541714
New
Federal
NSF X-Labs Initiative - From Sequence to Function
Solicitation # NSF-Topic4-FY26-XLabsSequence-to-Function
Tip - Core Programs

POSTED

about 24 hours ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Preclinical In Vivo Efficacy TestingThis subcontract involves performing preclinical in vivo efficacy testing for vaccine candidates on behalf of prime contractors for NIH/NIAID malaria vaccine projects. The scope of work includes administering vaccines to vertebrate animal models, monitoring immune responses, and conducting tissue analysis and euthanasia. To qualify, the provider must maintain an AAALAC-accredited vivarium with specialized housing for malaria-susceptible species and strictly adhere to AVMA Guidelines for the Euthanasia of Animals. The primary deliverables for this engagement are comprehensive animal study reports and preclinical efficacy data. This opportunity is associated with NAICS code 541714 and is managed under the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is February 11, 2027.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Specialized Vaccine Formulation ServicesThis subcontract for Specialized Vaccine Formulation Services supports the National Institutes of Health and the Department of Health and Human Services in advancing preclinical malaria vaccine projects. The selected provider will develop and test improved formulations and combination vaccine strategies for prime contractors, utilizing laboratory-scale equipment, stability chambers, and analytical tools such as HPLC or Mass Spec. Key responsibilities include performing formulation screening, stability testing, and the creation of delivery systems while maintaining strict compliance with federal laboratory safety and biohazard regulations. The primary deliverables for this engagement are validated vaccine formulations and comprehensive stability reports. Interested parties should note that the response deadline is February 11, 2027, and the work falls under NAICS code 541714.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)The National Institutes of Health is seeking applicants to establish Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications. These centers will provide essential resources and testing services to the biomedical community to advance the development of genome editing technologies for treating human diseases. By collaborating with NIH-funded investigators, the centers will evaluate the efficacy and safety of delivery technologies, establish editing thresholds to minimize off-target effects, and determine feasibility within various model systems. The initiative emphasizes the creation of in vivo and in vitro research models, with a specific interest in new approach methodologies and human-biology-based models to complement traditional methods. Testing Centers are expected to develop standardized assays and operating procedures to ensure scientific rigor and reproducibility. While focusing on a limited number of initial projects, these centers will build adaptable core systems designed to support a wide range of diseases and offer fee-for-service resources on a local, regional, and national scale.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Grant
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-024
The National Institutes of Health, under the Department of Health and Human Services, is soliciting applications for RFA-AI-28-024 to support the research and preclinical development of highly efficacious malaria vaccines. The initiative focuses on utilizing structure-based immunogen design, improved formulations, and combination vaccines to create long-lasting protection that can serve as a model for other mosquito-borne diseases. This funding opportunity is structured as a phased award, consisting of an R61 exploratory phase for up to three years with annual direct costs up to 400,000 dollars, and an R33 development phase for up to two years with annual direct costs up to 750,000 dollars. The maximum total project period is five years, and clinical trials are strictly prohibited. Applications will be evaluated through the NIH peer review system based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Key requirements include the establishment of quantifiable R61 transition milestones and clear translational Go/No-go criteria for vaccine candidates. Applicants must maintain active SAM registration and provide a Data Management and Sharing Plan. Additionally, recipients must adhere to strict cybersecurity protocols modeled after the NIST framework, including multifactor authentication and a 48-hour incident notification requirement, and ensure all research involving human subjects or vertebrate animals complies with federal regulations and ethical guidelines.
National Institutes Of Health

POSTED

2 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
High-Throughput Functional Genomic AssayingThis subcontract, titled High-Throughput Functional Genomic Assaying, supports National Institutes of Health and NHGRI research projects by providing experimental testing of genomic variants. The scope of work involves implementing high-throughput assays to perturb variants and executing functional interpretation strategies utilizing CRISPR-based systems and high-throughput screening platforms. The selected provider is responsible for delivering raw molecular and cellular data along with all associated metadata. The project is managed under the Department of Health and Human Services and requires strict adherence to 45 CFR Part 46 regulations regarding human subjects research. The opportunity was posted on October 9, 2026, with a response deadline of December 14, 2026. It is categorized under NAICS code 541714 for research and development in biotechnology.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in about 2 months
View Details

More opportunities from National Institutes Of Health → National Institute Of Allergy And Infectious Diseases

Same awarding agency

NAICS: 541715
Grant
Notice of Informational Webinar for RFA-AI-27-018, Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Solicitation # NOT-AI-26-004
The National Institute of Allergy and Infectious Diseases, in collaboration with the Office of AIDS Research and other participating offices, is hosting an informational webinar regarding solicitation RFA-AI-27-018. This initiative focuses on Implementation Science to Advance HIV Prevention, Treatment, and Care under the R61/R33 framework, where clinical trials are optional. The session is designed to allow prospective applicants to learn about key features of the program and engage with Program and Grants Management staff. The webinar is scheduled for October 19, 2026, from 1:30 PM to 3:00 PM EST. While attendance is encouraged to help applicants better understand the requirements, it is not a mandatory prerequisite for submitting an application. Interested parties must register in advance via the provided link, and those requiring reasonable accommodations are asked to submit their requests at least five days before the event.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

8 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)
Solicitation # RFA-AI-27-018
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking proposals for the Implementation Science to Advance HIV Prevention, Treatment, and Care initiative. This solicitation, identified as RFA-AI-27-018, focuses on supporting implementation research designed to enhance the uptake, sustainment, scale, and spread of evidence-based interventions within U.S. communities heavily impacted by HIV. The agency is prioritizing large-scale projects with significant potential for public health impact, specifically encouraging the submission of multi-site, single-site, or comparative studies. This funding opportunity is structured as an R61/R33 clinical trial optional award. Interested parties must submit their responses by the deadline of June 21, 2029. The primary goal of the selected projects will be to bridge the gap between evidence-based prevention and treatment strategies and their practical application in real-world community settings to improve overall health outcomes.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

in over 2 years
View Details
NAICS: 541714
Grant
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-031
The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is seeking applications for the Centers for Structural Biology of HIV and Other Infectious Diseases under solicitation RFA-AI-28-031. This funding opportunity aims to establish multidisciplinary consortia comprising structural biologists, microbiologists, and other experts dedicated to solving complex biological structures to advance the prevention, treatment, and cure of HIV and various other infectious diseases. Selected centers are expected to foster new collaborations, manage shared resources, and provide essential services to the broader research community while training future scientists in the field. The response deadline for this solicitation is May 29, 2027, and clinical trials are not allowed under this specific grant.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

13 days ago

DEADLINE

in 8 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS